TVM Capital Life Science Closes Fund at $201M

TVM Capital Life Science, a global life science venture capital firm, closed its latest fund at $201m.

Led by managing partners Dr. Luc Marengere and Dr. Hubert Birner, TVM Life Science Ventures VII Fund acquires early-stage molecules from pharmaceutical or biotechnology companies around the world, and then finances a virtual project-focused-company (PFC) for each of these molecules. The target is to develop each molecule through proof-of-concept (one or more clinical studies designed to determine whether a molecule has the potential to work in patients).

LPs include Teralys Capital, Eli Lilly and Company, the Business Development Bank of Canada, the Minnesota Life Insurance Company, CD Venture, Fondaction, Bukwang Pharma of South Korea.



Join the discussion